In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Innate Pharma (IPHA), with a price target of $11.50. The company’s shares closed last Tuesday at $4.10, close to its 52-week low of $3.55.
According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 30.2% and a 48.1% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Corvus Pharmaceuticals, and Cellectar Biosciences.
Currently, the analyst consensus on Innate Pharma is a Moderate Buy with an average price target of $8.19.
See today’s analyst top recommended stocks >>
Innate Pharma’s market cap is currently $323.8M and has a P/E ratio of -3.90. The company has a Price to Book ratio of 2.29.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body’s immune system to recognize and kill cancer cells. The company’s revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies.
